In:
Journal of Diabetes Research, Hindawi Limited, Vol. 2020 ( 2020-06-10), p. 1-7
Kurzfassung:
Objective . We aimed to evaluate whether the reduction in serum high-sensitivity C-reactive protein (hs-CRP) favors kidney outcomes. Methods . This study was a subanalysis including patients with impaired fasting glucose or diabetes of the Kailuan cohort study. The predictor was based on two consecutive visits of hs-CRP levels in 2006 and 2008. A total of 3924 patients with hs- CRP ≥ 3 mg / L in 2006 were divided into two groups according to whether the levels of hs-CRP were reduced in 2008: Group 1: no reduction: hs- CRP ≥ 3 mg / L in 2008; Group 2: reduction: hs- CRP 〈 3 mg / L in 2008. Kidney outcomes include kidney function decline and development and progression of proteinuria and were followed up until the end of 2015. Results . There were 3905, 2049, and 493 patients included into our analysis for the outcomes of kidney function decline and the development and progression of proteinuria, respectively. A total of 398, 297, and 47 events occurred after 5 years of follow-up, respectively. Cox regression revealed that patients with reduction in hs-CRP have lower risk of kidney function decline (HR 0.71, 95% CI 0.57-0.89, and P = 0.002 ) and development of proteinuria (0.77, 0.61-0.99, and P = 0.038 ) after controlling for potential confounders as compared to those with no reduction in hs-CRP levels. Conclusions . Reduction in serum hs-CRP levels favors kidney outcomes in patients with impaired fasting glucose or diabetes.
Materialart:
Online-Ressource
ISSN:
2314-6745
,
2314-6753
DOI:
10.1155/2020/2720905
Sprache:
Englisch
Verlag:
Hindawi Limited
Publikationsdatum:
2020
ZDB Id:
2711897-6
Permalink